Literature DB >> 34740813

Associations of pregnancy phthalate concentrations and their mixture with early adolescent bone mineral content and density: The Health Outcomes and Measures of the Environment (HOME) study.

Jordan R Kuiper1, Joseph M Braun2, Antonia M Calafat3, Bruce P Lanphear4, Kim M Cecil5, Aimin Chen6, Yingying Xu7, Kimberly Yolton7, Heidi J Kalkwarf7, Jessie P Buckley8.   

Abstract

BACKGROUND: The developing fetus may be particularly susceptibility to environmental osteotoxicants, but studies of pregnancy phthalate exposures and childhood bone health are scarce.
OBJECTIVES: To examine relations of pregnancy phthalate exposure biomarkers with early adolescent bone mineral density (BMD) and bone mineral content (BMC) in a prospective birth cohort.
METHODS: We used data from 223 pregnant mothers and their children enrolled in a Cincinnati, OH area cohort from 2003 to 2006. We quantified monoethyl phthalate (MEP), monoisobutyl phthalate, monobutyl phthalate, monobenzyl phthalate, mono-(3-carboxypropyl) phthalate (MCPP), and four metabolites of di-2-ethylhexyl phthalate in maternal urine collected at 16 and 26 weeks gestation, and calculated the average of creatinine-standardized concentrations. Using dual x-ray absorptiometry measures at age 12 years, we calculated BMD and BMC Z-scores for six skeletal sites. In overall and sex-stratified models, we estimated covariate-adjusted associations per 2-fold increase in phthalate biomarker concentrations using linear regression, and estimated joint effects of the phthalate biomarkers mixture using Bayesian kernel machine regression (BKMR) and quantile g-computation.
RESULTS: In single phthalate models, several biomarkers were positively associated with BMC and BMD. For example, each doubling of MEP and MCPP, 1/3rd distal radius BMD Z-score increased by 0.09 (95% CI: 0.01, 0.17) and 0.16 (95% CI: 0.01, 0.31), respectively. For phthalate mixtures, associations were generally U-shaped among males and positive-linear among females, using both statistical methods. Mixture associations were strongest with forearm sites: in BKMR models, increasing all biomarkers from the 50th to 90th percentile was associated with a 0.64 (95% CI: 0.01, 1.28) greater 1/3rd distal radius BMD Z-score in males, and a 0.49 (95% CI: -0.13, 1.10) greater ultradistal radius BMD Z-score in females. DISCUSSION: In this study, phthalate exposures during gestation were associated with increased BMD Z-scores in early adolescence, though further research is needed to determine implications for long-term skeletal health.
Copyright © 2021 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Adolescence; Bone mineral content; Bone mineral density; Phthalates; Pregnancy

Mesh:

Substances:

Year:  2021        PMID: 34740813      PMCID: PMC8671261          DOI: 10.1016/j.bone.2021.116251

Source DB:  PubMed          Journal:  Bone        ISSN: 1873-2763            Impact factor:   4.398


  94 in total

Review 1.  Estrogen and the skeleton.

Authors:  Sundeep Khosla; Merry Jo Oursler; David G Monroe
Journal:  Trends Endocrinol Metab       Date:  2012-05-16       Impact factor: 12.015

Review 2.  Bone and bone marrow disruption by endocrine-active substances.

Authors:  Dimitrios Agas; Giovanna Lacava; Maria Giovanna Sabbieti
Journal:  J Cell Physiol       Date:  2018-06-28       Impact factor: 6.384

3.  Age at onset of puberty predicts bone mass in young adulthood.

Authors:  Vicente Gilsanz; James Chalfant; Heidi Kalkwarf; Babette Zemel; Joan Lappe; Sharon Oberfield; John Shepherd; Tishya Wren; Karen Winer
Journal:  J Pediatr       Date:  2010-08-24       Impact factor: 4.406

4.  Activation of peroxisome proliferator-activated receptor-gamma inhibits differentiation of preosteoblasts.

Authors:  Emma Khan; Yousef Abu-Amer
Journal:  J Lab Clin Med       Date:  2003-07

5.  Critical years and stages of puberty for spinal and femoral bone mass accumulation during adolescence.

Authors:  J P Bonjour; G Theintz; B Buchs; D Slosman; R Rizzoli
Journal:  J Clin Endocrinol Metab       Date:  1991-09       Impact factor: 5.958

6.  The peroxisome proliferator-activated receptor (PPAR) alpha agonist fenofibrate maintains bone mass, while the PPAR gamma agonist pioglitazone exaggerates bone loss, in ovariectomized rats.

Authors:  Astrid K Stunes; Irene Westbroek; Björn I Gustafsson; Reidar Fossmark; Jan H Waarsing; Erik F Eriksen; Christiane Petzold; Janne E Reseland; Unni Syversen
Journal:  BMC Endocr Disord       Date:  2011-05-26       Impact factor: 2.763

7.  Estrogen Regulates Bone Turnover by Targeting RANKL Expression in Bone Lining Cells.

Authors:  Carmen Streicher; Alexandra Heyny; Olena Andrukhova; Barbara Haigl; Svetlana Slavic; Christiane Schüler; Karoline Kollmann; Ingrid Kantner; Veronika Sexl; Miriam Kleiter; Lorenz C Hofbauer; Paul J Kostenuik; Reinhold G Erben
Journal:  Sci Rep       Date:  2017-07-25       Impact factor: 4.379

8.  Different skeletal effects of the peroxisome proliferator activated receptor (PPAR)alpha agonist fenofibrate and the PPARgamma agonist pioglitazone.

Authors:  Unni Syversen; Astrid K Stunes; Björn I Gustafsson; Karl J Obrant; Lars Nordsletten; Rolf Berge; Liv Thommesen; Janne E Reseland
Journal:  BMC Endocr Disord       Date:  2009-03-30       Impact factor: 2.763

9.  Alterations in estrogen levels during development affects the skeleton: use of an animal model.

Authors:  S Migliaccio; R R Newbold; J A McLachlan; K S Korach
Journal:  Environ Health Perspect       Date:  1995-10       Impact factor: 9.031

Review 10.  A Review on the Effects of Bisphenol A and Its Derivatives on Skeletal Health.

Authors:  Kok-Yong Chin; Kok-Lun Pang; Wun Fui Mark-Lee
Journal:  Int J Med Sci       Date:  2018-06-22       Impact factor: 3.738

View more
  1 in total

1.  Serum PFAS and Urinary Phthalate Biomarker Concentrations and Bone Mineral Density in 12-19 Year Olds: 2011-2016 NHANES.

Authors:  Jenny L Carwile; Shravanthi M Seshasayee; Katherine A Ahrens; Russ Hauser; Jeffrey B Driban; Clifford J Rosen; Catherine M Gordon; Abby F Fleisch
Journal:  J Clin Endocrinol Metab       Date:  2022-07-14       Impact factor: 6.134

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.